Literature DB >> 7743513

Cytoplasmic localization of a mutant M(r) 160,000 topoisomerase II alpha is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line.

S E Mirski1, S P Cole.   

Abstract

Many clinically important antineoplastic agents exert their cytotoxicity through interaction with the M(r) 170,000 topoisomerase II alpha, an essential nuclear enzyme. Resistance to these agents has been associated frequently with either a decrease in the levels of topoisomerase II alpha or a qualitative change that alters the interaction of this enzyme with a drug or DNA. Using a VP-16-selected lung cancer cell line, H209/V6, we have identified a third resistance mechanism which involves an aberrant subcellular location of the topoisomerase II alpha isoenzyme. We have shown previously that H209/V6 cells express two topoisomerase II alpha mRNAs (6.1 and 4.8 kilobases) but only a single catalytically active protein which has a M(r) of 160,000 and is located primarily in the cytoplasm (Mirski et al., Cancer Res., 53: 4866-4873, 1993; Feldhoff et al., Cancer Res., 54: 756-762, 1994). In the present study we have determined that this mutant M(r) 160,000 topoisomerase II alpha is encoded by the shorter 4.8-kilobase mRNA. The sequencing of reverse transcriptase-PCR products from H209/V6 cells and subsequent Northern blot analyses showed that a sequence of 988 nucleotides from the 3'-coding and 3'-noncoding region of the normal topoisomerase II alpha is absent from the 4.8-kilobase mRNA. This shorter mRNA is predicted to encode a topoisomerase II alpha protein that no longer contains the 109 COOH-terminal amino acids of the normal enzyme but instead contains 34 new amino acids encoded by a sequence that was previously in the 3'-noncoding region of the mRNA. Confirmation that the COOH terminus of topoisomerase II alpha is no longer present in the M(r) 160,000 protein in H209/V6 cells was obtained by immunoblot analysis. Sequence analyses indicate that 3 putative bipartite nuclear localization signals in the M(r) 160,000 protein are disrupted or lost. Our results suggest that sequences within the COOH-proximal domain of human topoisomerase II alpha serve an important nuclear localization function.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7743513

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.

Authors:  Parvathi Ranganathan; Trinayan Kashyap; Xueyan Yu; Xiaomei Meng; Tzung-Huei Lai; Betina McNeil; Bhavana Bhatnagar; Sharon Shacham; Michael Kauffman; Adrienne M Dorrance; William Blum; Deepa Sampath; Yosef Landesman; Ramiro Garzon
Journal:  Clin Cancer Res       Date:  2016-06-29       Impact factor: 12.531

2.  Towards establishment of a plant-based model to assess the novel anti-cancerous lead molecule(s): An in silico, in vivo and in vitro assessment of some potential anti-cancerous drugs on Lathyrus sativus L.

Authors:  Aveek Samanta; Saptadipa Banerjee; Tilak Raj Maity; Jangala Jahnavi; Siraj Datta
Journal:  Protoplasma       Date:  2022-02-23       Impact factor: 3.186

3.  Use of CRISPR/Cas9 with homology-directed repair to silence the human topoisomerase IIα intron-19 5' splice site: Generation of etoposide resistance in human leukemia K562 cells.

Authors:  Victor A Hernandez; Jessika Carvajal-Moreno; Xinyi Wang; Maciej Pietrzak; Jack C Yalowich; Terry S Elton
Journal:  PLoS One       Date:  2022-05-26       Impact factor: 3.752

4.  Bimodal recognition of DNA geometry by human topoisomerase II alpha: preferential relaxation of positively supercoiled DNA requires elements in the C-terminal domain.

Authors:  A Kathleen McClendon; Amanda C Gentry; Jennifer S Dickey; Marie Brinch; Simon Bendsen; Anni H Andersen; Neil Osheroff
Journal:  Biochemistry       Date:  2008-12-16       Impact factor: 3.162

Review 5.  DNA topoisomerase II, genotoxicity, and cancer.

Authors:  A Kathleen McClendon; Neil Osheroff
Journal:  Mutat Res       Date:  2007-07-03       Impact factor: 2.433

6.  hsa-miR-9-3p and hsa-miR-9-5p as Post-Transcriptional Modulators of DNA Topoisomerase IIα in Human Leukemia K562 Cells with Acquired Resistance to Etoposide.

Authors:  Evan E Kania; Jessika Carvajal-Moreno; Victor A Hernandez; Anthony English; Jonathan L Papa; Nicholas Shkolnikov; Hatice Gulcin Ozer; Ayse Selen Yilmaz; Jack C Yalowich; Terry S Elton
Journal:  Mol Pharmacol       Date:  2019-12-13       Impact factor: 4.436

Review 7.  Nuclear transport inhibition in acute myeloid leukemia: recent advances and future perspectives.

Authors:  Chetasi Talati; Kendra L Sweet
Journal:  Int J Hematol Oncol       Date:  2018-09-11

8.  Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer.

Authors:  J Kreisholt; M Sorensen; P B Jensen; B S Nielsen; C B Andersen; M Sehested
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

9.  Nuclear interactions of topoisomerase II alpha and beta with phospholipid scramblase 1.

Authors:  Jessica P Wyles; Zhongqin Wu; Shelagh E L Mirski; Susan P C Cole
Journal:  Nucleic Acids Res       Date:  2007-06-12       Impact factor: 16.971

10.  DNA topoisomerase I and II expression in drug resistant germ cell tumours.

Authors:  D M Berney; J Shamash; J Gaffney; S Jordan; R T D Oliver
Journal:  Br J Cancer       Date:  2002-09-09       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.